

- E<sup>1</sup>
38. (Twice Amended) An antibody or [antigen binding] antigen-binding fragment thereof [which specifically binds to] having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5.
39. (Twice Amended) An antibody or [antigen binding] antigen-binding fragment of Claim 38, wherein the mammalian C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
- 
- E<sup>2</sup>
49. (Twice Amended) An antibody or [antigen binding] antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5, and the antibody or [antigen binding] antigen-binding fragment inhibits binding of a ligand to the receptor and inhibits function associated with binding of the ligand to the receptor.
50. (Twice Amended) The antibody or [antigen binding] antigen-binding fragment of Claim 49 wherein the antibody or antigen binding fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein or portion thereof.
51. (Twice Amended) The antibody or [antigen binding] antigen-binding fragment of Claim 49 which is 7B11 or an antigen binding fragment thereof.

E3 53. (Twice Amended) An antibody or [antigen binding] antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or the complement of SEQ ID NO: 1, 3 or 5, and the antibody or [antigen binding] antigen-binding fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein.

E4 55. (Twice Amended) The antibody or [antigen binding] antigen-binding fragment of Claim 53 which is 7B11 or an antigen binding fragment thereof.

ES 59. (Amended) A method of inhibiting at least one function of a mammalian chemokine receptor 3 protein, comprising the step of contacting said protein with an antibody or [antigen binding] antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian chemokine receptor 3 protein [or portion thereof], wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or the complement of SEQ ID NO: 1, 3 or 5, and said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein [or portion thereof].

60. (Amended) The method of Claim 59 wherein the antibody or fragment thereof is 7B11 or an [antigen binding] antigen-binding fragment thereof.

ES  
cont

61. (Amended) A method for treating an inflammatory disease or condition, comprising administering to a mammal a therapeutically effective amount of an antibody or [antigen binding] antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian chemokine receptor 3 protein [or portion thereof], wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or the complement of SEQ ID NO: 1, 3 or 5, and said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein [or portion thereof].

62. (Amended) The method of Claim 61 wherein the antibody or fragment thereof is 7B11 or an [antigen binding] antigen-binding fragment thereof.

E6

65. (Amended) A method of detecting or measuring human chemokine receptor 3 protein or a portion thereof on the surface of a cell, comprising contacting said cell with an antibody or [antigen binding] antigen-binding fragment thereof having binding specificity for a naturally-occurring human [mammalian] chemokine receptor 3 protein, wherein said naturally-occurring human C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or the complement of SEQ ID NO: 1, 3 or 5, and said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein.

E7

67. (Amended) The method of Claim 65 wherein the antibody or fragment thereof is 7B11 or an [antigen binding] antigen-binding fragment thereof.

E8

69. (Amended) A monoclonal antibody [or antigen binding fragment thereof] produced by the hybridoma cell line of Claim 68 or an antigen-binding fragment of said antibody.

70. (Amended) An antibody or [antigen binding] antigen-binding fragment thereof [which specifically binds to] having binding specificity for a naturally-occurring human C-C chemokine receptor 3 protein, wherein said naturally-occurring human C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5.
71. (Amended) An antibody or [antigen binding] antigen-binding fragment thereof having binding specificity for a naturally-occurring human C-C chemokine receptor 3 protein, wherein said naturally-occurring human C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5, and the antibody or [antigen binding] antigen-binding fragment inhibits binding of a ligand to the receptor and inhibits function associated with binding of the ligand to the receptor.
72. (Amended) The antibody or [antigen binding] antigen-binding fragment of Claim 71 wherein the antibody or [antigen binding] antigen-binding fragment can compete with monoclonal antibody 7B11 for binding to said human C-C chemokine receptor 3 protein.
73. (Amended) An antibody or [antigen binding] antigen-binding fragment thereof having binding specificity for a naturally-occurring human C-C chemokine receptor 3 protein, wherein said naturally-occurring human C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or the complement of SEQ ID NO: 1, 3 or 5, and the antibody or [antigen binding] antigen-binding fragment can compete with monoclonal antibody 7B11 for binding to said human C-C chemokine receptor 3 protein.

E<sup>8</sup>  
cont

- E<sup>9</sup>
75. (Amended) The antibody or [antigen binding] antigen-binding fragment of Claim 38 wherein said naturally-occurring mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid [comprising a] consisting of the nucleotide sequence [selected from the group consisting] of SEQ ID NO:1 or the complement thereof [, SEQ ID NO:3 and SEQ ID NO:5].

77. (Amended) The antibody or antigen-binding fragment of Claim 70 wherein said antibody or fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11[, and wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2].

- E<sup>10</sup>
78. (Amended) The antibody or antigen-binding fragment of Claim [70] 77 wherein [said antibody or fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11, and wherein] said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

79. (Amended) The antibody or antigen-binding fragment of Claim 70 wherein said antibody or fragment [can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2, and] is a humanized immunoglobulin or antigen-binding fragment comprising the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 and a human framework region.

E10  
Cont

80. (Amended) The antibody or antigen-binding fragment of Claim [70] 79 wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4[, and is a humanized immunoglobulin or antigen-binding fragment comprising the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 and a human framework region].

81. (Amended) A composition comprising the antibody or [antigen binding] antigen-binding fragment of Claim 38 and a physiologically acceptable vehicle or carrier.

---

Please add new Claims 87-150.

---87. The antibody or antigen-binding fragment of Claim 77 wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

88. The antibody or antigen-binding fragment of Claim 79 wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

E11

89. The antibody or antigen-binding fragment of Claim 38 wherein said naturally-occurring mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under high stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.

90. A composition comprising the antibody or antigen-binding fragment of Claim 75 and a physiologically acceptable vehicle or carrier.

91. The antibody or antigen-binding fragment of Claim 38 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment and a Fv fragment.

92. The antibody or antigen-binding fragment of Claim 49 wherein said naturally-occurring mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
93. The antibody or antigen-binding fragment of Claim 49 wherein said naturally-occurring mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under high stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
94. The antibody or antigen-binding fragment of Claim 49 wherein said ligand is selected from the group consisting of MCP-3, RANTES, MCP-2, MCP-4 and eotaxin.
95. The antibody or antigen-binding fragment of Claim 49 wherein said ligand is selected from the group consisting of MCP-3 and RANTES.
96. A composition comprising the antibody or antigen-binding fragment of Claim 92 and a physiologically acceptable vehicle or carrier.
97. The antibody or antigen-binding fragment of Claim 49 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment and a Fv fragment.
98. A composition comprising the antibody or antigen-binding fragment of Claim 49 and a physiologically acceptable vehicle or carrier.
99. The antibody or antigen-binding fragment of Claim 53 wherein said naturally-occurring mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.

E11  
cont.

100. The antibody or antigen-binding fragment of Claim 53 wherein said naturally-occurring mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under high stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
101. A composition comprising the antibody or antigen-binding fragment of Claim 53 and a physiologically acceptable vehicle or carrier.
102. The antibody or antigen-binding fragment of Claim 53 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment and a Fv fragment.
103. A composition comprising the antibody or antigen-binding fragment of Claim 99 and a physiologically acceptable vehicle or carrier.
104. The method of Claim 59 wherein said mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
105. The method of Claim 59 wherein said mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under high stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
106. The method of Claim 59 wherein said human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:2.
107. The method of Claim 59 wherein said human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:4.

Ell  
Cont.



108. The method of Claim 59 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment and a Fv fragment.
109. The method of Claim 61 wherein said mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
110. The method of Claim 61 wherein said mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under high stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
111. The method of Claim 61 wherein said human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:2.
112. The method of Claim 61 wherein said human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:4.
113. The method of Claim 61 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment and a Fv fragment.
114. The method of Claim 65 wherein said mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
115. The method of Claim 65 wherein said mammalian C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under high stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.

Ell  
Cont.

116. The method of Claim 65 wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 for binding to human C-C chemokine receptor 3 comprising the amino acid sequence of SEQ ID NO:2.
117. The method of Claim 65 wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 for binding to human C-C chemokine receptor 3 comprising the amino acid sequence of SEQ ID NO:4.
118. The method of Claim 65 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment and a Fv fragment.
119. The antibody or antigen-binding fragment of Claim 70 wherein said naturally-occurring human C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
120. The antibody or antigen-binding fragment of Claim 70 wherein said naturally-occurring human C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under high stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
121. The antibody or antigen-binding fragment of Claim 70 wherein said naturally-occurring human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:2.
122. The antibody or antigen-binding fragment of Claim 70 wherein said naturally-occurring human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:4.
123. The antibody or antigen-binding fragment of Claim 70 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment and a Fv fragment.

Ell  
Cont.

124. The antibody or antigen-binding fragment of Claim 70 wherein said antibody is a humanized or chimeric antibody or a humanized or chimeric antigen-binding fragment.
125. The antibody or antigen-binding fragment of Claim 71 wherein said naturally-occurring human C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
126. The antibody or antigen-binding fragment of Claim 71 wherein said naturally-occurring human C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under high stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
127. The antibody or antigen-binding fragment of Claim 71 wherein said naturally-occurring human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:2.
128. The antibody or antigen-binding fragment of Claim 71 wherein said naturally-occurring human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:4.
129. A composition comprising the antibody or antigen-binding fragment of Claim 125 and a physiologically acceptable vehicle or carrier.
130. The antibody or antigen-binding fragment of Claim 71 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment and a Fv fragment.
131. A composition comprising the antibody or antigen-binding fragment of Claim 71 and a physiologically acceptable vehicle or carrier.
132. The antibody or antigen-binding fragment of Claim 71 wherein said antibody is a humanized or chimeric antibody or a humanized or chimeric antigen-binding fragment.

Ell  
Contd

133. The antibody or antigen-binding fragment of Claim 71 wherein said ligand is selected from the group consisting of MCP-3, RANTES, MCP-2, MCP-4 and eotaxin.
134. The antibody or antigen-binding fragment of Claim 71 wherein said ligand is selected from the group consisting of MCP-3 and RANTES.
135. The antibody or antigen-binding fragment of Claim 73 wherein said naturally-occurring human C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
136. The antibody or antigen-binding fragment of Claim 73 wherein said naturally-occurring human C-C chemokine receptor 3 is encoded by a nucleic acid that hybridizes under high stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
137. The antibody or antigen-binding fragment of Claim 73 wherein said naturally-occurring human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:2.
138. The antibody or antigen-binding fragment of Claim 73 wherein said naturally-occurring human C-C chemokine receptor 3 comprises the amino acid sequence of SEQ ID NO:4.
139. A composition comprising the antibody or antigen-binding fragment of Claim 135 and a physiologically acceptable vehicle or carrier.
140. The antibody or antigen-binding fragment of Claim 73 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')<sub>2</sub> fragment and a Fv fragment.
141. A composition comprising the antibody or antigen-binding fragment of Claim 73 and a physiologically acceptable vehicle or carrier.

Ell  
Cont.

142. The antibody or antigen-binding fragment of Claim 73 wherein said antibody is a humanized or chimeric antibody or a humanized or chimeric antigen-binding fragment.
143. The antibody or antigen-binding fragment of Claim 53 wherein said antibody or fragment is a humanized or chimeric antibody or a humanized or chimeric antigen-binding fragment.
144. An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of nucleotide sequence of SEQ ID NO:3 or the complement thereof.
145. An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement thereof, and the antibody or antigen-binding fragment inhibits binding of a ligand to the receptor and inhibits function associated with binding of the ligand to the receptor.
146. An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring human C-C chemokine receptor 3 protein, wherein said naturally-occurring human C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes under moderate stringency conditions to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement thereof.

El  
cont.